Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
Makaleler > Tam Makale · 2008
Yazarlar: Emine Serra KAMER, Qing Ren, Adam P. Dicker
Archives of Gynecology and Obstetrics, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2008, cilt 279, ss 41-46
DOI: 10.1007/s00404-008-0667-7
Özet
Cervical cancer is one of the deadliest cancers in women with a death toll of 230,000 worldwide each year, nearly 80% in developing countries. Radiotherapy (RT) is a major treatment modality for advanced cervical cancer but the local relapse rate is 30-44% in patients treated with RT alone and 19-25% in patients treated with concurrent chemoradiotherapy. Previous studies have shown that the transcription factor NF-kappa B is constitutively expressed in human cervical squamous cell carcinomas. NF-kappa B activation also contributes to the resistance of cervical cancer cells to apoptosis induced by chemotherapeutic agents and radiation. Therefore, inhibition of NF-kappa B in tumor cells may render them more sensitive to chemo/radiation therapies. The objective of this study is to investigate the potential of radiosensitization of NF-kappa B inhibition by Velcade in human cervical cancer cell lines.